Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis for Prevention of Radiation Maculopathy
NCT00540930Phase 4Unknown
- Sponsor
- Shields, Shields & Associates
- Start
- Apr 2007
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in Radiation Maculopathy (RM), radiation retinopathy (RR), sponsored by Shields, Shields & Associates. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
Radiation Maculopathy (RM)radiation retinopathy (RR)
Beyond the preview
Go deeper on NCT00540930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00540930.